ALS Himalaya trial: a global, double-blind, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR443820, a RIPK1 inhibitor, in adult participants with ALS

Speakers: Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at MGH) and Dr. Nazem Atassi (Sanofi)
The webinar discussion will include the mechanism of action of RIPK1 inhibition, efficacy in animal models, results from Phase 1 first in human studies, and Phase 2 study design and update on enrollment.